231 related articles for article (PubMed ID: 28082680)
1. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.
Nadeau SA; An W; Mohapatra BC; Mushtaq I; Bielecki TA; Luan H; Zutshi N; Ahmad G; Storck MD; Sanada M; Ogawa S; Band V; Band H
J Biol Chem; 2017 Mar; 292(9):3666-3682. PubMed ID: 28082680
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
[TBL] [Abstract][Full Text] [Related]
3. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations.
Kassenbrock CK; Anderson SM
J Biol Chem; 2004 Jul; 279(27):28017-27. PubMed ID: 15117950
[TBL] [Abstract][Full Text] [Related]
4. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
[TBL] [Abstract][Full Text] [Related]
5. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
Javadi M; Richmond TD; Huang K; Barber DL
J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
[TBL] [Abstract][Full Text] [Related]
6. The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme.
Ryan PE; Sivadasan-Nair N; Nau MM; Nicholas S; Lipkowitz S
J Biol Chem; 2010 Jul; 285(31):23687-98. PubMed ID: 20525694
[TBL] [Abstract][Full Text] [Related]
7. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
Peschard P; Ishiyama N; Lin T; Lipkowitz S; Park M
J Biol Chem; 2004 Jul; 279(28):29565-71. PubMed ID: 15123609
[TBL] [Abstract][Full Text] [Related]
8. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
9. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
Rathinam C; Thien CB; Flavell RA; Langdon WY
Cancer Cell; 2010 Oct; 18(4):341-52. PubMed ID: 20951944
[TBL] [Abstract][Full Text] [Related]
10. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
11. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
13. Structural flexibility regulates phosphopeptide-binding activity of the tyrosine kinase binding domain of Cbl-c.
Takeshita K; Tezuka T; Isozaki Y; Yamashita E; Suzuki M; Kim M; Yamanashi Y; Yamamoto T; Nakagawa A
J Biochem; 2012 Nov; 152(5):487-95. PubMed ID: 22888118
[TBL] [Abstract][Full Text] [Related]
14. Loss of function Cbl-c mutations in solid tumors.
Daniels SR; Liyasova M; Kales SC; Nau MM; Ryan PE; Green JE; Lipkowitz S
PLoS One; 2019; 14(7):e0219143. PubMed ID: 31260484
[TBL] [Abstract][Full Text] [Related]
15. SLAP2 Adaptor Binding Disrupts c-CBL Autoinhibition to Activate Ubiquitin Ligase Function.
Wybenga-Groot LE; Tench AJ; Simpson CD; Germain JS; Raught B; Moran MF; McGlade CJ
J Mol Biol; 2021 Apr; 433(8):166880. PubMed ID: 33617900
[TBL] [Abstract][Full Text] [Related]
16. A mouse with a loss-of-function mutation in the c-Cbl TKB domain shows perturbed thymocyte signaling without enhancing the activity of the ZAP-70 tyrosine kinase.
Thien CB; Scaife RM; Papadimitriou JM; Murphy MA; Bowtell DD; Langdon WY
J Exp Med; 2003 Feb; 197(4):503-13. PubMed ID: 12591907
[TBL] [Abstract][Full Text] [Related]
17. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
[TBL] [Abstract][Full Text] [Related]
18. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
20. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
